RHBC
MRNA icon

R.H. Bluestein & Co’s Moderna MRNA Stock Holding History

R.H. Bluestein & Co’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$309K Sell
2,611
-500
-16% -$75.9K 0.02% 238
2022
Q2 		$444K Buy
3,111
+250
+9% +$35.7K 0.03% 178
2022
Q1 		$493K Sell
2,861
-250
-8% -$42.1K 0.02% 191
2021
Q4 		$790K Hold
3,111
– – 0.03% 138
2021
Q3 		$1.2M Hold
3,111
– – 0.05% 93
2021
Q2 		$731K Hold
3,111
– – 0.03% 170
2021
Q1 		$407K Hold
3,111
– – 0.02% 245
2020
Q4 		$325K Hold
3,111
– – 0.01% 263
2020
Q3 		$220K Sell
3,111
-2,000
-39% -$139K 0.01% 309
2020
Q2 		$328K Buy
+5,111
New +$280K 0.02% 217

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

R.H. Bluestein & Co's MRNA Position: Q3 2022 in Review

R.H. Bluestein & Co reduced its Moderna (MRNA) stake by 16% in Q3 2022, selling an estimated $75.9K and leaving 2,611 shares worth $309K. The position accounts for 0.02% of the portfolio, ranked #238.

R.H. Bluestein & Co first reported a position in MRNA in Q2 2020 and has held it in 10 quarters since. The position peaked at $1.2M in Q3 2021. 916 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • R.H. Bluestein & Co held 2,611 shares of Moderna worth $309K as of Q3 2022.
  • R.H. Bluestein & Co sold 500 Moderna shares in Q3 2022, an estimated $75.9K.
  • Moderna made up 0.02% of R.H. Bluestein & Co's portfolio in Q3 2022, its #238 holding.
  • R.H. Bluestein & Co first reported a position in Moderna in Q2 2020 and has held it in 10 quarters since.
  • R.H. Bluestein & Co's Moderna position peaked at $1.2M in Q3 2021.
  • 916 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on R.H. Bluestein & Co's 13F filing for Q3 2022, filed 14 Nov 2022.